These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6770 related articles for article (PubMed ID: 2945905)

  • 1. Increased T-helper lymphocytes following active specific intralymphatic immunotherapy of cancer.
    Wiseman C; Rao VS; Bakke A; Kerman R; Bouzaglou A; Presant C; McKenna RJ; Smith JD; Sakulsky SB
    J Biol Response Mod; 1986 Oct; 5(5):490-7. PubMed ID: 2945905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy.
    Williams TW; Yanagimoto JM; Mazumder A; Wiseman CL
    Mol Biother; 1992 Jun; 4(2):66-9. PubMed ID: 1515096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):29-36. PubMed ID: 11862469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
    Buckley DT; Robins AR; Durrant LG
    Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial.
    Wiseman CL; Rao VS; Kennedy PS; Presant CA; Smith JD; McKenna RJ
    West J Med; 1989 Sep; 151(3):283-8. PubMed ID: 2588564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
    Kosugi A; Fujiwara H; Hamaoka T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte profiles in patients with chronic low back pain enrolled in a clinical trial.
    Brennan PC; Graham MA; Triano JJ; Hondras MA; Anderson RJ
    J Manipulative Physiol Ther; 1994 May; 17(4):219-27. PubMed ID: 8046277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of T cell-derived helper factor production upon stimulation with pokeweed mitogen in humans.
    Suzuki N; Sakane T
    Clin Exp Immunol; 1988 Feb; 71(2):343-9. PubMed ID: 2964963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of CD4+ T helper cell clones in human melanoma.
    Goedegebuure PS; Lee KY; Matory YL; Peoples GE; Yoshino I; Eberlein TJ
    Cell Immunol; 1994 Jun; 156(1):170-9. PubMed ID: 7911074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell subpopulations defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. II. Activated and functional subsets of helper-inducer and cytotoxic-suppressor subpopulations defined by two-colour fluorescence flow cytometry.
    Atkinson K
    Bone Marrow Transplant; 1986 Dec; 1(2):121-32. PubMed ID: 2971408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
    Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
    Bonehill A; Heirman C; Thielemans K
    J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 339.